BUND FINANCE

BUND FINANCE › Stocks › NVO

Novo Nordisk A/S (NVO)

NYSE · Stock price, chart and technical analysis

US$38.87-0.5600 (-1.42%)

Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$39.43
OpenUS$39.36
Day rangeUS$38.61 – US$39.81
52-week rangeUS$35.12 – US$64.16
Market capUS$171.31B
Volume16.51M
50-day averageUS$39.80
200-day averageUS$42.95
Beta0.35
Last dividend per shareUS$1.80

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueDKK 140.8BDKK 177.0BDKK 232.3BDKK 290.4BDKK 309.1B
Net incomeDKK 47.8BDKK 55.5BDKK 83.7BDKK 101.0BDKK 102.4B
EPS (diluted)10.3712.2218.6222.6323.03
Gross margin83.2%83.9%84.6%84.7%81.0%
Operating margin41.7%42.3%44.2%44.2%41.3%
Net margin33.9%31.4%36.0%34.8%33.1%
Free cash flowDKK 47.6BDKK 64.1BDKK 70.0BDKK 69.7BDKK 29.0B
Total debtDKK 26.6BDKK 25.8BDKK 27.0BDKK 102.8BDKK 131.0B
CashDKK 10.7BDKK 12.7BDKK 14.4BDKK 15.7BDKK 26.5B

Compound annual growth: revenue 21.7% · net income 21.0% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E—30.5x26.4x
EV / EBITDA—22.1x16.3x
Operating margin42.4%—3.6%
Net margin33.9%—-0.0%
Debt / equity1.75—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation. The company reports in another currency: amounts are shown in that currency.

About Novo Nordisk A/S

SectorHealthcare
IndustryDrug Manufacturers - General
CountryDK
CEOMaziar Mike Doustdar
Employees68,794
IPO date1981-04-30

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone…

www.novonordisk.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice